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The regulation of mRNA stability has emerged as a critical control step in dynamic gene 
expression. This process occurs in response to modifications of the cellular environ-
ment, including hormonal variations, and regulates the expression of subsets of proteins 
whose levels need to be rapidly adjusted. Modulation of messenger RNA stability is 
usually mediated by stabilizing or destabilizing RNA-binding proteins (RNA-BP) that 
bind to the 3′-untranslated region regulatory motifs, such as AU-rich elements (AREs). 
Destabilizing ARE-binding proteins enhance the decay of their target transcripts by 
recruiting the mRNA decay machineries. Failure of such mechanisms, in particular mis-
expression of RNA-BP, has been linked to several human diseases. In the adrenal cortex, 
the expression and activity of mRNA stability regulatory proteins are still understudied. 
However, ACTH- or cAMP-elicited changes in the expression/phosphorylation status of 
the major mRNA-destabilizing protein TIS11b/BRF1 or in the subcellular localization of 
the stabilizing protein Human antigen R have been reported. They suggest that this level 
of regulation of gene expression is also important in endocrinology.
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iNtrODUctiON
Transcriptional regulation of the cellular responses to hormones has been the primary focus of 
many endocrinological research studies during the past decades. Although the transcriptional 
mechanisms that regulate the production of specific mRNAs are undoubtedly important, it has 
become increasingly evident that processes regulating the stability of mRNAs also represent critical 
steps in the control of dynamic gene expression. In particular, acute changes in gene expression 
are now recognized to be controlled by RNA-binding proteins (RNA-BP) and microRNAs through 
their binding to target transcripts and their positive or negative regulation of mRNA turnover. 
Because the ability to respond to rapid changes in ACTH levels is essential for maintaining steroid 
hormone homeostasis, posttranscriptional mechanisms are expected to be involved in ACTH action. 
The pleiotropic effects exerted by ACTH on adrenocortical cell functions are regulated through 
a multiplicity of mechanisms. Through binding to its adenylate-cyclase-coupled receptor MC2R, 
ACTH stimulates the release of cAMP and the activation of the cAMP-dependent protein kinase 
A (PKA), which in turn phosphorylates and regulates a number of specific substrates including the 
steroidogenic acute regulatory protein (StAR) (1) and the cAMP response element-binding protein 
(CREB) (2). ACTH also strongly regulates the transcription of a number of genes involved in the 
Abbreviations: TIS11b, TPA-inducible sequence 11b; BRF1, butyrate response factor 1; ZFP36, zinc finger protein; TTP, 
tristetraprolin; CCR4, carbon catabolite repressor protein 4; CNOT1, CCR4-NOT transcription complex subunit 1; Dcp1a, 
decapping enzyme 1a.
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steroidogenic response including those encoding several steroi-
dogenic enzymes (3), components of the extracellular matrix (4) 
and many others. Another less characterized level of regulation 
through which ACTH exerts its actions is the control of mRNA 
stability through the activity of specific proteins that bind the 
3′-untranslated region (3′-UTR) of target mRNAs. We were first 
to observe that the increase in vascular endothelial growth factor-
A (VEGF-A) mRNA induced by ACTH in primary adrenocorti-
cal fasciculata cells did not result from increased transcription 
(5) but from stabilization of its mRNA (6). Here, we will present 
the proteins that mediate the regulation of short-lived mRNA 
stability/degradation and focus on those which are regulated by 
ACTH in adrenocortical cells.
mrNA stABiLitY MecHANisMs: AN 
iNterPLAY BetWeeN CIS-ActiNG 
eLeMeNts AND TRANS-ActiNG 
FActOrs
The steady-state level of any mRNA in an eukaryotic cell results 
from the balance between its synthesis through gene transcrip-
tion and its degradation through the mRNA decay machinery. 
Regulation of mRNA stability implies both cis elements mainly 
located in the 3′-UTR of mRNAs and trans-acting factors. These 
latter factors comprise a number of RNA-BP that specifically bind 
distinct cis elements, form multimolecular scaffolds that favor or 
prevent the subsequent recruitment of the mRNA deadenylation 
and mRNA degradation machineries (Figure 1A) (7). Eukaryotic 
mRNAs are protected at both extremities by a 7-methyl guano-
sine cap at their 5′-end that confers resistance to 5′ to 3′ exo-
nucleases and by a poly(A)-tail recruiting the poly(A)-binding 
protein (PABP) at their 3′-end that confers resistance to 3′ to 5′ 
exonuclease attack by the exosome complex (8). The most fre-
quently distributed and best-studied cis elements are the AU-rich 
elements (AREs) that are often arranged in mRNA 3′-UTRs as 
repeated AUUUA pentameric sequences that eventually overlap 
(9). More than 6,000 human ARE-containing mRNAs have been 
listed in the last upgrade of the ARED 3.0 database (http://brp.
kfshrc.edu.sa/ARED/) (10). Many of them have a short half-life, 
rendering this regulatory process highly effective to rapidly turn 
down a cellular function.
Ares BiNDiNG PrOteiNs
Among the more than 20 ARE-binding proteins (ARE-BP) iden-
tified so far, some are destabilizing the target mRNA by recruiting 
deadenylases and exonucleases and some are stabilizing them by 
protecting them from these degradation enzymes. The competi-
tion between both types of proteins for a given ARE will ultimately 
determine the fate of the target mRNA. The best characterized 
stabilizing ARE-BP is human antigen R (HuR), which is a mem-
ber of the ELAV (homologs of the Drosophila proteins embryonic 
lethal abnormal vision) family (11). HuR is ubiquitously expressed 
and is predominantly localized in the nucleus of non-stimulated 
cells where it forms messenger ribonucleoprotein complexes 
that are assembled during splicing of primary transcripts, prior 
to transport of mature mRNAs to the cytoplasm (12). Upon cell 
activation by various stimuli, HuR undergoes CRM1-dependent 
nuclear-cytoplasmic shuttling, directed by localization signals 
(13). Binding of HuR to ARE may play important roles in control-
ling the processing, splicing, and polyadenylation of the nuclear 
transcript, together with the nuclear export and stabilization/
translation in the cytoplasm. The exact mechanism by which 
HuR stabilizes target mRNAs is still unclear, but HuR has been 
reported in many cell types to prevent the degradation of target 
mRNAs by competing with destabilizing proteins and thereby 
preventing their recruitment of the exosome machinery (6, 14). 
A larger number of destabilizing proteins has been described. 
Among them, the tristetraprolin (TTP) family, which comprises 
three distinct members in mammals (TTP/TIS11/ZFP36, 
TIS11b/BRF1/ZFP36-L1, and TIS11d/BRF2/ZFP36-L2) is one of 
the best characterized. Although they all bind to similar synthetic 
sequences in vitro, members of the TTP family present specific 
sites of action and preferential targets in vivo, as demonstrated 
by the distinct phenotypes of the mice that have been genetically 
invalidated for each of these genes. In TTP-KO mice, the TNFα 
mRNA is significantly stabilized in macrophages, resulting in a 
fatal postnatal inflammatory syndrome (15). Deletion of TIS11b/
BRF1 gene in mice results in embryonic lethality due to abnormal 
placentation and major vascular defects (16, 17). This is mainly 
caused by the failure of TIS11b to repress the expression of VEGF 
at the end of the developmental angiogenic process. The com-
plete invalidation of the TIS11d gene causes postnatal lethality 
due to defective definitive hematopoiesis (18). Structural studies 
have shown that the tandem zing finger repeats of TTP family 
proteins bind to the 5′-UUAUUUA(U/A)(U/A)-3′ recognition 
motif while the C-terminal and N-terminal domains of the pro-
teins participate in the recruitment of the mRNA deadenylation 
and mRNA degradation enzymes (19, 20). Other destabilizing 
ARE-BP include KH-splicing regulatory protein (KSRP) and the 
AU-rich RNA-binding factor 1 (AUF1/HnRNP D).
ActH ActiON ON mrNA DecAY 
MecHANisMs: FrOM trANscriPtiON 
tO PHOsPHOrYLAtiON OF Are-BP
TIS11b, also named BRF1 or ZFP36-L1, was identified in the 
adrenal cortex through a differential display RT-PCR analysis 
of ACTH-stimulated versus non-stimulated adrenocortical cells 
(21). HuR and alternatively spliced isoforms of AUF1/hnRNPD 
are also expressed in adrenal cells (6, 22). Recently, it was estab-
lished that ACTH induced zfp36-L1 gene transcription in bovine 
adrenocortical cells (BAC) through phosphorylation of CREB 
transcription factor and CREB-mediated activation of TIS11b 
promoter (23). A highly conserved cAMP response element 
(CRE) was found at -402 to -394 relative to the transcription start 
site (TSS) of human zfp36-L1 gene. TIS11b mRNA is also rapidly 
stimulated by 8-bromo-cAMP in murine adrenocortical Y-1 cells 
or Leydig MA-10 cells (22), suggesting that the protein is a key 
regulator of endocrine tissue biology. Interestingly, no classical 
CRE was identified within the −2,000 bp upstream of the TSS of 
the two other family members TTP and TIS11d. In agreement 
FiGUre 1 | Function of tristetraprolin (ttP) and tis11b in Are-mediated mrNA decay. (A) TTP and TIS11b bind to AU-rich elements in the 3′-UTR of 
target mRNAs and recruit the deadenylase complex directly (CCR4–CAF–NOT1 complex) to trigger mRNA deadenylation. Deadenylated transcripts are degraded 
through TTP- or TIS11b-mediated recruitment of the exosome, a multiprotein complex that promotes the 3′ to 5′ mRNA decay. Alternatively, deadenylation can be 
followed by mRNA decapping by the decapping enzymes Dcp1/Dcp2 and the 5′ to 3′ mRNA degradation by the Xrn1 exonuclease. CDS, coding sequence. (B) 
Two putative protein kinase A (PKA) phosphorylation sites, S54 and S334, were identified in TIS11b protein sequence with important roles in protein activity and 
stability. ACTH stimulation increases intracellular cAMP levels through the action of the G protein Gs and the adenylyl cyclase. This leads to activation of PKA (1). 
Phosphorylation of TIS11b at S54 by PKA inhibits protein activity. TIS11b-phospho-S54 is sequestered in the cytoplasm due to enhanced interaction with 14-3-3 
proteins. This mechanism would promote vascular endothelial growth factor (VEGF) mRNA induction (2). To turn down VEGF production, phosphorylation of TIS11b 
at S334 by PKA increases protein stability and activity. Dephosphorylation of both serines presumably by the phosphatase PP2A leads to degradation of TIS11b via 
the proteasome.
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with this observation, TTP or TIS11d mRNA levels were not 
changed upon ACTH challenge, pointing at a specific induction 
of TIS11b by the hormone in the adrenal cortex (23).
Two major target transcripts of TIS11b have been identified 
in the adrenal cortex. The first one is the message encoding the 
angiogenic cytokine VEGF (24). Knowing that VEGF mRNA 
was rapidly but transiently induced by ACTH in fasciculata cells 
through a transcription-independent mechanism, the contribu-
tion of TIS11b and HuR to this transient induction was investi-
gated. Using HuR- and TIS11b-specific siRNAs, it was established 
that (i) ACTH induced nucleo-cytoplasmic translocation of HuR 
to trigger VEGF mRNA stabilization in the cytoplasm and (ii) 
TIS11b, which is induced later by ACTH, participates in the 
downregulation of VEGF mRNA levels. A short 75-bp long 
sequence in VEGF mRNA 3′-UTR was shown to bind TIS11b 
through two adjacent UUAUUUAAU and AUUUA motifs. The 
second identified target of TIS11b in endocrine cells is the StAR 
mRNA whose PKA-stimulated transcription paralleled TIS11b 
induction (22). StAR mediates intramitochondrial cholesterol 
transport in most steroidogenic tissues in response to hormonal 
changes (1). Cyclic AMP stimulates two major StAR transcripts 
of 3.5 and 1.6 kb, which arise from differential use of polyadenyla-
tion signals and therefore differ only in their 3′-UTR (lengths 
0.7 and 2.8  kb, respectively). In mouse MA-10 and Y-1 cells, 
8-bromo-cAMP stimulates StAR 3.5-kb mRNA as the predomi-
nant form. In BAC, similar long and short forms appear equally 
(21), whereas in human adrenocortical carcinoma cells H295R, 
di-butyryl-cAMP selectively stimulates the short form of StAR 
mRNA (25). Following translation, the 3.5-kb StAR message is 
preferentially degraded after removal of the stimulus through the 
action of TIS11b binding to UAUUUAUU repeats in the extended 
3′-UTR. This attenuation process provides a rapid mechanism to 
inactivate StAR when hormonal stimulation ceases.
ARE-binding proteins are also distal targets of several signal-
ing pathways. TTP and TIS11b are phosphorylated by a variety of 
protein kinases. However, the impact of these phosphorylations on 
their mRNA-destabilizing activity is still a matter of debate, with 
some studies indicating that phosphorylations of TTP decrease 
its affinity for ARE-rich mRNAs (26) and other studies reporting 
that phosphorylations by ERK, p38 MAP-Kinase/MK2, or JNK 
kinase do not impact this affinity (27). Similarly, phosphorylation 
of TIS11b by PKB/Akt or MK2 at conserved serine residues did 
not affect its ability to bind AREs but nevertheless inhibited its 
ability to promote ARE-mRNA degradation (28, 29). The current 
accepted model suggests that protein-kinase activation leads to 
phosphorylation of TTP or TIS11b, favors their sequestration by 
14.3.3 proteins, and thereby reduces their mRNA-destabilizing 
action. Upon signal extinction, dephosphorylation of TTP 
and TIS11b occurs probably via protein phosphatase PP2A 
and allows the recruitment of the mRNA decay ribonucleases. 
A new ACTH-regulated phosphorylation site recently identi-
fied in TIS11b seems, however, to mediate a different biological 
response. ACTH-mediated activation of PKA was reported to 
induce the phosphorylation of TIS11b on two serine residues, 
S54 and S334 (23) (Figure 1B). Analysis of phospho-dead (S54A, 
S334A) and phospho-mimick (S54D, S334D) TIS11b mutants 
revealed that S54 regulates the binding of TIS11b to 14.3.3 protein 
but that S334 does not play a significant role in this interaction. 
In contrast, the C-terminal S334 phospho-site appears to be 
involved in the interaction with the CCR4–NOT1 deadenylation 
complex. TIS11b S334D phospho-mimick mutants presented a 
reduced association with CNOT1, a core subunit of the CCR4–
NOT deadenylase complex, but however displayed an enhanced 
interaction with the decapping enzyme Dcp1a. Unexpectedly, this 
interaction was associated with an increased mRNA-destabilizing 
activity of TIS11b S334D as compared to the dephospho-form 
of TIS11b (23). These observations suggest that combinatorial 
phosphorylations of TIS11b on specific residues do not system-
atically abrogate their mRNA-destabilizing capability but rather 
fine-tune their interactions with the mRNA decay machineries.
eXPressiON OF ttP FAMiLY MeMBers 
iN ADreNOcOrticAL tUMOrs
Overexpression of ARE-containing transcripts encoding factors 
promoting growth, inflammation, angiogenesis, and invasion has 
been observed in carcinogenesis (30). These aberrant expressions 
results from dysfunctional ARE-mediated posttranscriptional 
control, which seems to be mainly due to deregulations in ARE-
binding proteins rather than to ARE mutations. Downregulation 
of TTP expression has been found in a variety of human 
malignancies including breast, colon, prostate, and lung cancers 
(31–33). The loss of TTP expression seems to be an early event 
during tumorigenesis. Nevertheless, apart from single-nucleotide 
polymorphisms associated with decreased translation efficiency, 
the mechanisms leading to TTP suppression in cancer remain 
obscure. Analysis of the mRNA expression levels of TTP fam-
ily members (TTP, TIS11b, and TIS11d) and HuR in human 
adrenocortical tumors revealed that TTP mRNA was dramatically 
decreased in adrenocortical adenoma (ACA) and adrenocortical 
carcinomas (ACC) as compared to normal adrenal cortex (NAC) 
(Figure  2). By contrast, TIS11b mRNA is highly expressed in 
ACC as compared to ACA and NAC while the expression of the 
third member of the family TIS11d was similar in all the tissues 
examined. No significant difference in HuR expression was found 
between normal cortex and adrenocortical tumors. Remarkably, 
the expression patterns of TTP and TIS11b are symmetrically 
opposite in normal adrenal cortex and malignant tumors. The 
relevance of these variations to human physiology and the 
pathology of adrenocortical cancer remains to be determined. In 
addition, these results will require validation by measurement of 
TTP and TIS11b protein levels.
cLOsiNG reMArKs AND PersPectives
Transcriptional regulation has been considered the primary 
control point of protein production in eukaryotic cells. However, 
there is growing evidence of pivotal posttranscriptional regula-
tion for many genes, including those involved in differentiated 
functions of the adrenal cortex such as the StAR gene. This has 
prompted extensive investigations to elucidate the mechanisms 
controlling RNA processing, mRNA nuclear export and localiza-
tion, mRNA stability, and turnover, in addition to translational 
FiGUre 2 | expression of mrNA stability regulators in human adrenocortical tumors. Relative expression of mRNA stability factors in adrenocortical tumor 
samples from the French COMETE (COrtico et MEdullosurrénales, Tumeurs Endocrines) Network. TTP family members (TTP, TIS11b, and TIS11d) and HuR were 
quantified by reverse transcription-quantitative PCR in 4 normal adrenal cortex, 11 cortisol-producing adrenocortical adenomas, and 15 adrenocortical carcinomas. 
RPL13A was used as housekeeping gene for normalization. The graphs show median with interquartile range. All data were analyzed using the GraphPad Prism 
Software and were considered as statistically different when p < 0.05 (*) and p < 0.01 (**).
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rates and posttranslational events. The regulation of mRNA 
stability has emerged as a critical control step in determining the 
cellular mRNA level, which is regulated through specific RNA 
sequence elements–protein interactions. In this context, study 
of the hormonal control of mRNA stability regulatory proteins 
and their activity in adrenal cortex function is just beginning. 
Considering that acute ACTH treatment affects a large number 
of transcripts, it seems very likely that mRNA stability regulations 
might play an important role in these transient gene expressions. 
These mechanisms are expected to also operate in response to 
other cAMP-mobilizing hormones in their respective target 
organs. For example, parathyroid hormone has been shown to 
decrease sodium/hydrogen exchanger 3 mRNA stability through 
the action of the destabilizing protein KSRP in kidney epithelial 
cells (34). Importantly, few mRNA stability regulatory factors 
have been identified so far that appear to control a large pool of 
target mRNAs. This suggests that a slight alteration in the control 
mechanism may generate large-scale effects that could contribute 
to the development of complex disorders, including adrenal dis-
eases. Efforts in studying mRNA stability regulators in adrenal 
cortex and their hormonal regulations should be made in order 
to better understand their potential contribution to adrenocorti-
cal pathologies and possibly discover potential biomarkers and 
therapeutic targets.
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